| Date Filed | Type | Description |
| 08/11/2023 |
SC 13D/A
| RA CAPITAL MANAGEMENT, L.P. reports a 33.7% stake in VOR BIOPHARMA INC. |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
4
| Chakraborty Tirtha (Chief Scientific Officer) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 875 shares
@ $2.67, valued at
$2.3k
|
|
| 08/09/2023 |
4
| Jorgensen Nathan D. (CFO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 834 shares
@ $2.67, valued at
$2.2k
|
|
| 08/09/2023 |
4
| Attar Eyal C. (Chief Medical Officer) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 999 shares
@ $2.67, valued at
$2.7k
|
|
| 08/09/2023 |
4
| ANG ROBERT (President and CEO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 2,361 shares
@ $2.67, valued at
$6.3k
|
|
| 06/09/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data |
| 06/02/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| Resnick Joshua (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| Patterson Matthew R (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| Lubner David Charles (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| Lundberg Sven Ante (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 06/02/2023 |
4
| Beckman Daniella (Director) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 30,000 options to buy
@ $4.79, valued at
$143.7k
|
|
| 05/26/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/10/2023 |
4
| ANG ROBERT (President and CEO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 2,361 shares
@ $4.14, valued at
$9.8k
|
|
| 05/10/2023 |
4
| Chakraborty Tirtha (Chief Scientific Officer) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 875 shares
@ $4.14, valued at
$3.6k
|
|
| 05/10/2023 |
4
| Jorgensen Nathan D. (CFO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 834 shares
@ $4.14, valued at
$3.5k
|
|
| 05/10/2023 |
4
| Attar Eyal C. (Chief Medical Officer) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 969 shares
@ $4.14, valued at
$4k
|
|
| 04/14/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/14/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/14/2023 |
8-K
| Quarterly results |
| 03/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/02/2023 |
4
| ANG ROBERT (President and CEO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 12,657 shares
@ $5.51, valued at
$69.7k
|
|
| 03/02/2023 |
4
| Chakraborty Tirtha (Chief Scientific Officer) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 5,576 shares
@ $5.51, valued at
$30.7k
|
|
| 03/02/2023 |
4
| Jorgensen Nathan D. (CFO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Paid exercise price by delivering 6,310 shares
@ $5.51, valued at
$34.8k
|
|
| 02/14/2023 |
SC 13G/A
| Paradigm Biocapital Advisors LP reports a 9.9% stake in Vor Biopharma Inc. |
| 02/08/2023 |
4
| ANG ROBERT (President and CEO) has filed a Form 4 on Vor Biopharma Inc.|
Txns:
| Granted 128,750 shares
@ $0
Granted 257,500 options to buy
@ $5.55, valued at
$1.4M
|
|
| 02/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/10/2023 |
SC 13G/A
| FMR LLC reports a 12.1% stake in VOR BIOPHARMA INC |
| 12/21/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
|